Episode Details

#Zepbound #Wegovy #Tirzepatide #Semaglutide #glp1 

Zepbound and Wegovy are the two most talked-about weight loss medications right now — but the headlines comparing them skip the context that actually matters. In this video, I break down how tirzepatide (Zepbound) and semaglutide (Wegovy) actually work in your body, compare the real clinical trial data — including the new SURMOUNT-5 head-to-head trial — and walk through the side effects, cost, and questions you need to bring to your physician before choosing between them.

I'm Dr. Mohammed Paika — board-certified in Internal Medicine and Obesity Medicine, and a practicing hospitalist for over 15 years. I built DrMohammedPaika.com to give people real, evidence-based guidance on GLP-1 medications, nutrition, and exercise, because a prescription without a plan for your muscle, your nutrition, and your training is only half a treatment.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps

00:00 Introduction
01:10 Who's Giving You This Information
03:22 Wegovy vs. Zepbound: The Timeline
04:52 How These Medications Actually Work
07:28 Dosing and What's New in 2026
10:01 Side Effects (And a Case From My Hospital)
13:11 Who Actually Qualifies
14:09 The Individual Trial Data: STEP 1 vs. SURMOUNT-1
15:22 SURMOUNT-5: The Head-to-Head Trial
17:28 Why the Average Doesn't Decide Your Case
18:17 The Part Everyone Skips: Your Muscle
20:16 What These Medications Cost in 2026
22:36 A Patient Case That Changed My Approach
24:14 Questions to Ask Your Physician
25:22 The Bottom Line
26:26 Where to Go From Here

References 

Aronne LJ, et al. SURMOUNT-5, N Engl J Med (2025); Eli Lilly official results announcement, investor.lilly.com
Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157
U.S. FDA approval history: semaglutide (Ozempic) 2017; semaglutide (Wegovy) June 2021
Samms RJ, Coskun T, et al. Trends Endocrinol Metab. 2020;31(6):410-421
Coskun T, Sloop KW, et al. Mol Metab. 2018;18:3-14
Wegovy (semaglutide) U.S. Prescribing Information, Novo Nordisk
Zepbound (tirzepatide) U.S. Prescribing Information, Eli Lilly
FDA approval of oral semaglutide (Wegovy pill), OASIS-4 trial, 2025
Wilding JPH, et al. STEP 1. N Engl J Med. 2021;384:989-1002
Jastreboff AM, et al. SURMOUNT-1. N Engl J Med. 2022;387:205-216
He L, et al. JAMA Intern Med. 2022 (DOI 10.1001/jamainternmed.2022.0338)
Neeland IJ, et al. Diabetes Obes Metab. 2024 (DOI 10.1111/dom.15728)
Prado CM, Phillips SM, et al. Lancet Diabetes Endocrinol. 2024 (DOI 10.1016/S2213-8587(24)00272-9)
NovoCare.com, Wegovy Cost, Coverage & Savings Resources, 2026
Eli Lilly investor announcement, LillyDirect Self Pay Journey Program pricing, 2026

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educationa